Effect of vitamin D supplementation on management of anemia in hemodialysis patients with vitamin D deficiency: A double-blind, randomized, controlled trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in the context of anemia in this randomized controlled trial publication.

Anemia and vitamin D deficiency are common problems among hemodialysis (HD) patients.

Who Took Part

According to the abstract, 100 patients were involved.

This double-blind, randomized, controlled study included 100 anemic HD patients with vitamin D deficiency who were randomly divided using the closed envelop method into two groups (1:1).

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Neither the patients nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

Some patients received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

What Was Measured

Topics PubMed links to this paper include Renal Dialysis, Hemoglobins, Anemia, Vitamin D, Vitamin D Deficiency, Kidney Failure, Chronic and Dietary Supplements.

The authors tagged it with the keywords end-stage renal disease and hemodialysis.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 100 patients in people with anemia.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (Hemodialysis international. International Symposium on Home Hemodialysis), a journal based in Canada.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Anemia research.